Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (He FH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol.
The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined. D., Vice President of Cardiovascular & Metabolism Therapeutics, Regeneron.
In the , the recommended starting dose for Praluent is 75 mg once every two weeks administered subcutaneously, or alternatively, 300 mg once every four weeks (monthly) for patients who prefer less frequent dosing.
The agency is also recommending that pharmacists who receive prescriptions for drugs with more than the 325mg per dose call the prescribing physician and inform him of the FDA’s new warning.
(alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol.
(Michelle Tribe via Wikimedia Commons) Apparently, a Food and Drug Administration warning four months ago was missed by many physicians, pharmacists and patients, so the agency, in an unusual move, saw fit Monday to remind us: Stop writing prescriptions for, stop dispensing prescriptions for, and stop taking prescription medications containing more than 325 milligrams of acetaminophen.
Your liver will thank you -- acetaminophen overdose has overtaken viral hepatitis infection as the most common cause of acute liver failure.